Abstract. Previous studies have demonstrated that connective tissue growth factor (CTGF) is expressed at increased levels in prostate cancer bone metastasis mouse models and patients with prostate cancer which metastasizes to the bone; however, the underlying molecular mechanism(s) remain unknown. The present study investigated the function of CTGF in osteoblast differentiation and its effect on prostate cancer bone metastasis by analyzing CTGF gene expression and transcription at different levels of invasion, metastasis of prostate cancer cells, and the influence of CTGF on proliferation and xenotransplantation. A mouse model demonstrating bone metastasis was used to investigate the function(s) of CTGF in bone metastasis and osteoblast differentiation. Results demonstrated that CTGF expression was increased in association with high bone metastasis in prostate cancer cells, and its expression was significantly decreased in whole cell lysates. CTGF expression in prostate cancer cells with high levels of bone metastasis was increased 1.9-fold compared with prostate cancer cells with low levels of bone metastasis. The expression of CTGF in mesenchymal cells was markedly increased compared with epithelial cells. Results indicated that the increased expression of CTGF does not affect the proliferation of tumor cells and possesses no influence on tumor volume. Control and CTGF plasmids were transfected into RM1 cells and led to 4 and 17% bone lesions, respectively. Increased expression of CTGF significantly enlarged the tumor area in the bone metastatic position compared with the control. Positive areas of alkaline phosphatase were significantly decreased as the concentration of CTGF increased. The results of the present study demonstrated that CTGF promotes prostate carcinoma to metastasize in the bone by dysregulating osteoblast differentiation.
Introduction
Prostate cancer is one of the most common cancers among men, which affects one in seven men in the US (1) . Theoretically, prostate cancer cells may spread anywhere in the body. If prostate cancer spreads to other parts of the body, bone is the preferred location for prostate cancer to metastasize to, which results in complications including bone pain, pathological fractures, spinal compression and hypercalcemia (2) . Osteogenesis serves an important function in osteolytic bone lesions.
Connective tissue growth factor (CTGF) is a matricellular protein that belongs to the extracellular matrix-associated heparin-binding protein family (3, 4) , which has notable functions in numerous different biological processes, including cell migration and proliferation (5) . Previous experimental studies demonstrate that CTGF expression levels are high in mouse models and patients with primary prostate cancer that have metastasized to the bone (6) . CTGF possesses multiple functions in different types of cancer cell (7) .
Previous studies have demonstrated that CTGF possesses an inhibitory function in the development of brain glioma, melanoma and prostate cancer cells (8) . However, in contrast, a previous study has identified that CTGF has a facilitating effect on the metastasis of melanoma in addition to being able to promote the proliferation, migration and metastasis of Ewing sarcoma cells, and increasing expression levels result in an undesirable prognosis (9) . To the best of our knowledge, the Effects of connective tissue growth factor on prostate cancer bone metastasis and osteoblast differentiation functional mechanisms of CTGF in association with prostate cancer metastasizing within the bone remain unclear.
The present study investigated the effect of CTGF on prostate cancer bone metastasis using RM1 murine prostate cancer cell line and analyzed the underlying molecular mechanisms regarding to mouse osteoblast differentiation dysregulation.
Materials and methods
Cell culture. All experiments of the present study were approved by the ethics committee of The First Hospital of Qiqihar (Heilongjiang, China; no. 2015017). Mouse prostate cancer cells RM1, PNEC30, P25.48, MyC-CaP and VCaP cell line of human prostate cancer exhibited different metastatic capacities (10) , and were purchased from the American Association for Cancer Research (Philadelphia, PA, USA). Cells were cultured in Dulbecco's modified Eagle's medium containing Ham's F12 (Corning Incorporated, Corning, NY, USA), and placed in a 5% CO 2 incubator at 37˚C and passaged once cells reached confluency. Following the incubation period, cells were resuspended in 0.25% trypsin/0.02% EDTA solution for 3 min at room temperature.
Total RNA extraction and quantitative polymerase chain reaction (qPCR). RNA was isolated using TRIzol™ Reagent (15596026, Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) according to the manufacturer's protocol. cDNA was prepared from primary cultured astrocytes using Fast Lane Cell cDNA Kit (Qiagen, CA, USA) by using 500 ng RNA, and levels of mRNA were assessed using SYBR supermix (1708880, Bio-Rad, CA, USA). The thermocycling conditions were as follows: 95˚C for 3 min, 39 cycles of 95˚C for 30 sec, 60˚C for 30 sec and 72˚C for 30 sec. The following forward (F) and reverse (R) primers were used to amplify CTGF and actin: CTGF (F) 5-GAT GTA CGG AGA CAT GGC GT-3, CTGF (R) 5-AGT AGG CAC ACT GCT GCT TT-3 (primer blast, NCBI, USA); actin (F) 5-GAG ATT ACT GCC CTG GCT CCT A-3, actin (R) 5-TCA TCG TAC TCC TGC TTG CTG AT-3 (11) (Invitrogen, Thermo Fisher Scientific, Inc.). Gene level was calculated using the 2 -ΔΔCq method and presented as relative fold change (12) .
Western blotting. Total protein was extracted from RM1, PNEC30 and P25.48 cell lines using RIPA buffer (Beyotime, Beijing, China). The protein concentration was determined using a bicinchoninic acid protein assay kit. Protein samples (10 µg) were separated using denaturing SDS-PAGE (10% gel) and transferred onto a polyvinylidene fluoride membrane. The membrane was blocked in PBS/5% skimmed milk at room temperature for 1 h, followed by an incubation period with primary antibody (anti-CTGF: 1:1,000; cat. no. ab6992; Abcam, Cambridge, UK) and α-tubulin (T9026, 1:5,000, Sigma-Aldrich, Merck KGaA, Darmstadt, Germany) overnight at 4˚C. Secondary antibody (anti-rabbit horseradish peroxidase conjugated antibody, 1:5,000; cat. no. ab99848; Abcam and anti-mouse HRP antibody, 1:5,000; Bio-Rad Laboratories, Inc., Hercules, CA, USA) was added prior to incubation at room temperature for 1 h. Protein was visualized using enhanced chemiluminscence reagent (Thermo Fisher Scientific, Inc., Waltham, MA, USA). Expression levels of protein were analyzed using ImageJ analysis software (V.2.1.4.7, National Institutes of Health, Bethesda, MD, USA).
Immunohistochemical analysis. Paraffin specimens confirmed by pathology were collected from a patient with prostate cancer which had metastasized to the bone. Patient was male, 55 years old, and the sample was collected at the Department of Orthopedic Surgery at The First Hospital of Qiqihaer City (Quiqihaer, China) in December 2015. Paraffin specimens (fixed in 4% paraformaldehyde at 4˚C for at least 48 h and then were cut into 5 µm thick slices) were processed using anti-CTGF immunohistochemical staining. Subsequent to being blocked using 2% bovine serum albumin at room temperature for 1 h (BSA; Amresco, LLC, Solon, OH, USA), the primary antibody, anti-CTGF antibody (1,400; cat. no. ab6992; Abcam), was applied to the specimens overnight at 4˚C. Following incubation, the secondary antibody, biotin-labeled sheep anti-mouse antibody (1:1,000; cat no. A0277s; Beyotime Institute of Biotechnology, Haimen, China), was added. All photographs were captured using a Zeiss Axioplan 2 microscope (Carl Zeiss AG, Oberkochen, Germany). Immunostained slides were analyzed using the Image-Pro Plus system (Media Cybernetics, Inc., Rockville, MD, USA).
Cell proliferation assay. An automated cell counter (Cellometer; Nexcelom Bioscience LLC, Lawrence, MA, USA) was used to analyze cell proliferation. RM1 cells (8x10 3 cells/well) were transfected with empty vector or stable overexpression of CTGF in 12-well plates and incubated for 48 h. Following incubation, a number of cells (5x10 6 ) were removed daily for a total of 4 days, for further experiments.
Tumor metastasis assay. A C57BL/6 mouse model carrying a form of bone metastasis, developed according to Kubota and Takigawa (5) , was used to investigate prostate cancer and orthotopic implantation. The model was established by the subcapsular implantation of histologically intact prostate tumor tissues into the prostate gland of C57BL6 syngeneic mice (male; Vital River, Beijing, China; 20-25 g; 2-3 months old). The numbers of mice were 13, 14, 52, 56 respectively (Fig. 4A) , the diameter of tumor pieces were <3 mm, which were harvested from a subcutaneous tumor by RM1 cells. All animals were maintained on a 12-h light/dark cycle at 20-25˚C and had free access to food and water. The subcutaneous implantation model was used as a control. Alterations in carcinoma tumor volume(s) (volume calculation formula: πLW2/6, where L is length and W is width) in situ and the survival rate time(s) were recorded. X-radiography (XPERT80-L; Kubtec, Stratford, CT, USA) was used to record radiographs on the effects of implantation after 7 days. Bone samples from the model were collected and fixed in 4% paraformaldehyde overnight at room temperature. Samples were stored in 70% ethanol, embedded in paraffin, sagittally sectioned at 7 µm, and stained with hematoxylin and eosin, according to standard methods (13) . Samples were imaged using a Zeiss Axioplan 2 microscope (Carl Zeiss, Inc., Thornwood, NY, USA).
Osteoblast differentiation. Bone marrow cells (2-4x10
5 ) were obtained from mouse tibia and femur. Following overnight culture, 50 ng/ml ascorbic acid (AA; Merck KGaA) which was able to induce the differentiation of osteoblast cells, was added, and 600 ng/ml BSA (Amresco, LLC) and 600 ng/ml CTGF were added to the control group and experimental group respectively every 2 days for a 9-day period. Cells were fixed with 4% paraformaldehyde for 10 min at room temperature, washed with PBS and then alkaline phosphatase (ALP) staining was performed using Fast Red (F4381; Merck KGaA), according to the manufacturer's protocol. Image analysis software BIOQUANT Imaging Extensions (Bioquant Image Analysis Corporation, Nashville, TN, USA) was used to perform statistical analysis and calculate the mean covering rate.
Statistical analysis. Statistical analysis was performed using SPSS (version 16.0; SPSS, Inc., Chicago, IL, USA). All measurement data are presented as the mean ± standard deviation. A paired Student's t-test was used for all measurement data analyzed using VassarStats software (http://vassarstats. net/). Enumeration data were analyzed using the χ 2 goodness-of-fit test. All experiments were performed at least three times. P<0.05 indicated a statistically significant difference. demonstrated that CTGF mRNA expression was significantly increased in aggressive bone metastatic prostate cancer cells (P= 0.032; Fig. 1A ). Western blotting results demonstrated that CTGF protein expression in whole cell lysate and culture supernatant was significantly decreased in high bone metastatic prostate cancer cells (P= 0.025); however, secretory CTGF protein levels in cell culture supernatant was markedly increased compared with prostate cancer cells with a weaker metastatic potential (P= 0.0011; Fig. 1B ). In the ELISA, CTGF secreted by aggressively metastatic prostate cancer cells (MyC-CaP, P25.48 and VCaP cell lines) was increased 1.9-fold compared with weakly metastatic prostate cancer cells (RM1 and PNEC30 cell lines; P= 0.002; Fig. 1C ).
Results

Increased expression of CTGF in highly metastatic prostate cancer cells. Reverse transcription-qPCR analysis
Increased CTGF expression levels in patients with prostate cancer bone metastasis. Immunohistochemical staining detecting CTGF expression levels in clinical samples demonstrated mid to deep staining (scoring 2-4) in bone metastasis samples. Expression of CTGF in mesenchymal cells was markedly increased compared with epithelial cells (P= 0.013; Fig. 2A) . Results indicate that high CTGF expression levels in mesenchymal and epithelial cells was a common characteristic of prostate cancer with bone metastasis.
Increased CTGF expression levels do not promote tumor cell proliferation and xenotransplantation. RM1 cells were transfected with an empty plasmid and a CTGF plasmid to produce a stable RM1 cell line. CTGF expression in whole cell lysate and culture supernatant was significantly increased in RM1 cells (Fig. 3A and B) . The in vitro amplification curve demonstrated that high expression levels of CTGF had no significant effect on the proliferation of tumor cells (P>0.05). RM1 cell lines that were implanted into mice demonstrated that increased CTGF expression levels would not cause an alteration in tumor volume (P>0.05; Fig. 3C and D) .
Increased expression of CTGF promotes bone metastasis in prostate cancer. The incidence of bone metastasis in mice injected with control plasmid was 14% (2/14), whereas mice injected CTGF plasmids had an incidence of 31% (4/13; Fig. 4A ). Bone lesions caused by RM1 cells transfected with control plasmids and CTGF plasmids were significantly different (P=0.025). The area of tumors with RM1 cells transfected with CTGF was 1.7-fold larger compared with that with RM1 cells transfected with a control plasmid (P=0.018; Fig. 4B) . Results demonstrate that CTGF may significantly improve the ability of bone metastasis in primary prostate cancer.
CTGF causes dysregulation in osteoblast differentiation. ALP staining was used to calculate the mean coverage of osteoblast differentiation. The ability of osteoblast differentiation significantly increased following the addition of AA (P=0.006; Fig. 5A and B) . However, when adding AA and CTGF simultaneously, the staining area was significantly decreased as the concentration of CTGF increased (P= 0.014). Results demonstrated that CTGF promoted prostate cancer bone metastasis by causing dysregulation in osteoblast differentiation.
Discussion
The association between CTGF expression levels and prostate cancer with bone metastasis has been investigated previously (14) . Previous reports demonstrated that CTGF increased in cancer tissue (15) , which is consistent with the results of the present study, and it had different regulation abilities and effects on different types of tumor cell (16) (17) (18) (19) . Bennewith et al (20) demonstrated that CTGF protects cells from hypoxia-mediated apoptosis, providing an in vivo selection for tumor cells that express high levels of CTGF. Meanwhile, Kwon et al (21) revealed that CTGF is induced by TGF-β in diverse cell types, and CTGF was impaired in pancreatic cancers and cell lines. In different types of cancer cell, particularly breast and prostate, there are increased levels of CTGF expression, which are associated with a poor clinical outcome for patients (22, 23) . Furthermore, previous research demonstrated that CTGF had an association with vasculogenesis, infiltration and metastasis of malignancy tumor (24) .
Results from the present study demonstrated that the transcription and expression levels of CTGF were increased in prostate cancer cells that were highly metastatic, and the level of CTGF secreted from these cells was increased 1.7-fold compared with prostate cancer cells that had a decreased metastatic ability (low metastasis). This indicated that CTGF may be able to promote metastasis and invasion of prostate cancer. Increased CTGF expression levels in liver cancer, brain glioma and infiltrative gastric carcinoma may exacerbate medical conditions and decrease overall survival rates compared with diseases that have low levels of CTGF (25) . Results of the present study suggested that the same biological functions of CTGF are present in prostate cancer cells and that high levels of expression are present in highly metastatic cells. Increased expression levels of CTGF was the primary characteristic of prostate cancer bone metastasis, with no significant difference between mesenchymal and epithelial cells.
CTGF may promote the occurrence, differentiation, proliferation, pathological fracture healing and bone mass maintenance of cartilage and osteogenesis. Overexpression of CTGF may promote the expression of type X collagen in HCS-2/8 chondrosarcoma cells and the secretion of chondroproteoglycan (26) . CTGF also promotes the adhesion of osteoblasts by inhibiting the combination of fibrinogen and integrin receptors and inhibit the synthesis of osteocalcin in rat osteoblast-like cells (27) . Collectively, these previous studies indicate that CTGF serves a key function in regulating bone transformation and metastasis.
The present study demonstrated that increased expression levels of CTGF were not able to promote the proliferation of cancer cells, and also had no influence on alterations in tumor volume by xenotransplantation of RM1 cells. However, increased levels of CTGF expression may be able to promote bone metastasis in primary prostate cancer. Furthermore, ALP staining experiments demonstrated that bone metastasis in prostate cancer was caused by the dysregulation of osteoblast differentiation. However, further research is required to clarify the underlying molecular mechanism(s) of CTGF in promoting bone formation.
In summary, the results of the present study identified that CTGF promotes the bone metastatic process of prostate cancer by dysregulating the differentiation of osteoblasts, and forms tumor microenvironment characteristics for osteolytic metastatic carcinoma. These identified characteristics provide an evidence base for the development of effective prevention strategies and therapeutic options for patients with prostate cancer, as well as having important implications in the prevention of bone metastasis.
